- The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South AfricaJulie H Levison
Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
Clin Infect Dis 56:587-97. 2013..After adherence counseling, these patients may safely and effectively continue first-line ART, thereby delaying more expensive second-line ART...
- Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South AfricaJulie H Levison
Division of General Medicine Massachusetts General Hospital, Boston, Massachusetts, United States of America
PLoS ONE 7:e32144. 2012..We investigated the prevalence of wild-type virus (no major drug resistance) and drug resistance mutations at second-line antiretroviral treatment (ART) failure in a large HIV treatment program in South Africa...
- Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South AfricaJulie H Levison
Division of General Medicine, Massachusetts General Hospital, Boston, MA, USA
Antivir Ther 16:853-61. 2011..We aimed to describe predictors of lack of virological suppression in HIV-infected patients on second-line ART in a roll-out programme in South Africa...
- Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trialSarah B Lorenzana
Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
AIDS 26:1083-93. 2012..To project the clinical and economic outcomes of a genotype assay for selection of third-line antiretroviral therapy (ART) in resource-limited settings, as per the planned international A5288 trial (MULTI-OCTAVE)...